cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oramed Pharmaceuticals Inc
5 own
12 watching
Current Price
$1.94
$0.01
(0.52%)
logo-ormp
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
75.88M
52-Week High
52-Week High
13.73
52-Week Low
52-Week Low
1.81
Average Volume
Average Volume
1.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization75.88M
icon52-Week High13.73
icon52-Week Low1.81
iconAverage Volume1.58M
iconDividend Yield--
iconP/E Ratio--
What does the Oramed Pharmaceuticals Inc do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Read More
How much money does Oramed Pharmaceuticals Inc make?
News & Events about Oramed Pharmaceuticals Inc.
PR Newswire
18days ago
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed...
PR Newswire
26days ago
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023 /PRNewswire/ --Oramed...
PR Newswire
1month ago
Oramed Letter to Shareholders Oramed Letter to Shareholders PR Newswire NEW YORK, Dec. 21, 2022 Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023Phase 2 NASH Trial Achieved Primary and Secondary EndpointsDefinitive Deal Signed to Commercialize Oral Insulin in South Korea $160...
PR Newswire
2 months ago
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire NEW YORK, Nov. 17, 2022 Achieved primary endpoint of...
PR Newswire
3 months ago
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine PR Newswire NEW YORK, Oct. 7, 2022 Primary and secondary endpoints of safety and immunogenicity met Oral...
Frequently Asked Questions
Frequently Asked Questions
What is Oramed Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Oramed Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Oramed Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Oramed Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Oramed Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Oramed Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Oramed Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Oramed Pharmaceuticals Inc?
plus_minus_icon
What percentage is Oramed Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Oramed Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.94
$0.01
(0.52%)
logo-ormp
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00